Zhong Hua, Lu Jun, Wang Mengzhao, Han Baohui
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Respiratory & Critical Care Medicine, Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
J Comp Eff Res. 2025 Feb;14(2):e240043. doi: 10.57264/cer-2024-0043. Epub 2024 Dec 17.
The treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic therapy to the era of molecular biology-oriented targeted therapy and immunotherapy. As the first tyrosine kinase inhibitor (TKI) targeting the pathway, crizotinib is widely used as a first-line regimen for -rearranged NSCLC. However, due to the paucity of solid data from randomized, controlled phase III clinical studies, clinicians often require more systematic, real-world data-based guidance for its optimal clinical use. As one of the leading countries of real-world research on crizotinib, China has contributed significantly to data on standardization of the therapeutic use of crizotinib, including its clinical treatment patterns, the timing and duration of treatment and drug resistance monitoring and management.
非小细胞肺癌（NSCLC）的治疗已从以组织学为导向的细胞毒性疗法发展到以分子生物学为导向的靶向治疗和免疫治疗时代。作为首个靶向该通路的酪氨酸激酶抑制剂（TKI），克唑替尼被广泛用作ALK重排NSCLC的一线治疗方案。然而，由于缺乏来自随机对照III期临床研究的确切数据，临床医生在其最佳临床应用方面通常需要更系统的、基于真实世界数据的指导。作为克唑替尼真实世界研究的主要国家之一，中国在克唑替尼治疗应用标准化数据方面做出了重大贡献，包括其临床治疗模式、治疗时机和持续时间以及耐药性监测与管理。
